erocycles.5 Previously, we also established a series of
sequential reactions wherein an allene intermediate, generated
in situ, would undergo [4 + 2] cycloaddition reaction under
mild conditions, providing an efficient synthesis of structur-
ally complex polycycles with 2,3-dihydrofuran units,6 struc-
turally diverse fused dihydroisobenzofuran derivatives,7 and
polysubstituted pyridines and isoquinolines.8
The hydroisoindolone core is present in both synthetic and
naturally occurring compounds that exert a wide range of
pharmacological activities.9 For example, naturally occurring
fungal metabolites such as cytotoxic cytochalasin B10 and
recently discovered anti-HIV cytochalasin L-696,47411 both
contain the hydroisoindolone skeleton (Figure 1).
the intermediate N-(alk-4-en-2-ynyl)alk-2-enamides 4 which
would be generated from copper-catalyzed coupling of
vinylalkynes 1, imines 2, and R,ꢀ-unsaturated enoic acid
chlorides 3,13 may undergo subsequent propargyl-allenyl
isomerization reaction in the presence of a base leading to
the vinylallenes 5. An intramolecular [4 + 2] cycloaddition
may then proceed to furnish the highly substituted tetrahydro-
1H-isoindolones 6 (Scheme 1). Thus, by our strategy, three
Scheme 1
Figure 1. Several hydroisoindolone derivatives reported as biologi-
cally active compounds and pharmaceutical products.
new carbon-carbon bonds and one carbon-nitrogen bond
could be formed in a single stroke with the efficient assembly
of two rings from readily available starting materials.
Furthermore, because of the rigidity of the intermediate
vinylallenes 5, this intramolecular [4 + 2] cyclization was
anticipated to lead to polycycle 6 in a highly diastereose-
lective manner.14
While numerous methods have been reported for the
synthesis of isoindolone derivatives, they are generally
limited with respect to stereoselectivity and the types and
locations of substituents. In our continuous efforts to design
sequential reactions via allene intermediates,12 we report here
a sequential three-component copper-catalyzed coupling/
propargyl-allenyl isomerization/[4 + 2] cyclization reaction:
We initiated our study by attempting the reaction of 1a,
2a, and 3a (1.2:1:1.2) (Scheme 2). After being stirred at room
(4) (a) Ma, S.; Lu, P.; Lu, L.; Hou, H.; Wei, J.; He, Q.; Gu, Z.; Jiang,
X.; Jin, X. Angew. Chem., Int. Ed. 2005, 44, 5275. (b) Jiang, X.; Kong,
W.; Chen, J.; Ma, S. Org. Biomol. Chem. 2008, 6, 3606. (c) Padwa, A.;
Meske, M.; Murphree, S. S.; Watterson, S. H.; Ni, Z. J. Am. Chem. Soc.
1995, 117, 7071. (d) Wender, P. A.; Jenkins, T. E.; Suzuki, S. J. Am. Chem.
Soc. 1995, 117, 1843. (e) Padwa, A.; Filipkowski, M. A.; Meske, M.;
Watterson, S. H.; Ni, Z. J. Am. Chem. Soc. 1993, 115, 3776. (f) Kanematsu,
K.; Sugimoto, N.; Kawaoka, M.; Yeo, S.; Shiro, M. Tetrahedron Lett. 1991,
32, 1351.
Scheme 2
(5) (a) Braun, R. U.; Ansorge, M.; Mu¨ller, T. J. J. Chem.sEur. J. 2006,
12, 9081. (b) Braun, R. U.; Zeitler, K.; Mu¨ller, T. J. J. Org. Lett. 2001, 3,
3297. (c) D’Souza, D. M.; Kiel, A.; Herten, D. P.; Mu¨ller, T. J. J.
Chem.sEur. J. 2008, 14, 529. (d) Braun, R. U.; Zeitler, K.; Mu¨ller, T. J. J.
Org. Lett. 2000, 2, 4181. (e) D’Souza, D. M.; Rominger, F.; Mu¨ller, T. J. J.
Angew. Chem., Int. Ed. 2005, 44, 153. (f) D’Souza, D. M.; Rominger, F.;
Mu¨ller, T. J. J. Chem. Commun. 2006, 4096.
temperature for 1 h in the presence of CuI and Et3N, the
reaction gave N-(alk-4-en-2-ynyl)alk-2-enamide 4a in 85%
yield and no vinylallene or Diels-Alder product was
detected.
Subsequently, different bases were tested to promote the
propargyl-to-allenyl isomerization and [4 + 2] cycloaddition
reaction (Table 1). Weak bases such as triethylamine or
K2CO3 could not trigger the reaction, while a stronger
(6) Shen, R.; Huang, X. Org. Lett. 2008, 10, 3283.
(7) Shen, R.; Huang, X.; Chen, L. AdV. Synth. Catal. 2008, 350, 2865.
(8) Sha, F.; Huang, X. Angew. Chem., Int. Ed. 2009, 48, 3458.
(9) (a) Jiang, J.; Devita, R. J.; Kumar, S.; Mills, S. G.; Tschirret-Guth,
R. A. Int. Patent WO 2007002457, 2007. (b) Kuethe, J. T.; Yin, J.; Huffman,
M. A.; Journet, M. Int. Patent WO 2007008564, 2007. (c) Rudd, J. A.;
Ngan, M. P.; Wai, M. K. Eur. J. Pharmacol. 1999, 366, 243. (d) Walling,
E. A.; Drafft, G. A.; Ware, B. R. Arch. Biochem. Biophys. 1988, 264, 321.
(10) (a) Haidle, A. M.; Myers, A. G. Proc. Natl. Acad. Sci. U.S.A. 2004,
101, 12048. (b) Thilly, W. G.; Liber, H. L.; Wogan, G. N. Front. Biol.
1978, 46, 53.
(13) Black, D. A.; Arndtsen, B. A. Org. Lett. 2004, 6, 1107.
(14) (a) Deutsch, E. A.; Snider, B. B. J. Org. Chem. 1982, 47, 2682.
(b) Deutsch, E. A.; Snider, B. B. Tetrahedron Lett. 1983, 24, 3701. (c)
Keck, G. E.; Kachensky, D. F. J. Org. Chem. 1986, 51, 2487. (d) Gibbs,
R. A.; Bartels, K.; Lee, R. W. K.; Okamura, W. H. J. Am. Chem. Soc.
1989, 111, 3717. (e) Curtin, M. L.; Okamura, W. H. J. Org. Chem. 1990,
55, 5278. (f) Krause, N. Liebigs Ann. Chem. 1993, 521.
(11) Linghan, R. B.; Hsu, A.; Silverman, K. C.; Bills, G. F.;
Dombrowski, A.; Goldman, M. E.; Darke, P. L.; Huang, L.; Koch, G.;
Ondeyka, J. G.; Goetz, M. A. J. Antibiot. 1992, 45, 686.
(12) (a) Shen, R.; Zhu, S.; Huang, X. J. Org. Chem. 2009, 74, 4118.
(b) Huang, X.; Zhu, S.; Shen, R. AdV. Synth. Catal. 2009, 351, 3118. (c)
Shen, R.; Chen, L.; Huang, X. AdV. Synth. Catal. 2009, 351, 2833.
Org. Lett., Vol. 12, No. 21, 2010
5049